Modeling MLN8237, an aurora kinase a inhibitor, with irinotecan (IRN) and temozolomide (TMZ) in neuroblastoma (NB)

被引：3
|
作者：
Lipsitz, E. G.
Nguyen, V.
Zhao, H.
Ecsedy, J.
Maris, J. M.
Adamson, P. C.
Mosse, Y. P.
机构：
[1] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[2] Childrens Hosp, Philadelphia, PA 19104 USA
[3] Millennium Pharmaceut Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.10593
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10593
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays
    Manfredi, Mark G.
    Ecsedy, Jeffrey A.
    Chakravarty, Arijit
    Silverman, Lee
    Zhang, Mengkun
    Hoar, Kara M.
    Stroud, Stephen G.
    Chen, Wei
    Shinde, Vaishali
    Huck, Jessica J.
    Wysong, Deborah R.
    Janowick, David A.
    Hyer, Marc L.
    Leroy, Patrick J.
    Gershman, Rachel E.
    Silva, Matthew D.
    Germanos, Melissa S.
    Bolen, Joseph B.
    Claiborne, Christopher F.
    Sells, Todd B.
    CLINICAL CANCER RESEARCH, 2011, 17 (24) : 7614 - 7624
  • [32] Phase 1 study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States
    Infante, J.
    Dees, E. C.
    Cohen, R. B.
    Burris, H.
    O'Neil, B.
    Murphy, P.
    Lee, Y.
    Pappas, J.
    Ecsedy, J. A.
    Eton, O.
    EJC SUPPLEMENTS, 2008, 6 (12): : 90 - 91
  • [33] Alisertib (MLN8237), an Aurora Kinase A inhibitor, enhances Docetaxel-induced cell death in Upper Gastrointestinal Adenocarcinoma cells
    Sehdev, Vikas
    Revetta, Frank
    Belkhiri, Abbes
    Ecsedy, Jeffrey
    Zaika, Alexander
    El-Rifai, Wael
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [34] Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors
    Shah, Hiral A.
    Fischer, James H.
    Venepalli, Neeta K.
    Danciu, Oana C.
    Christian, Sonia
    Russell, Meredith J.
    Liu, Li C.
    Zacny, James P.
    Dudek, Arkadiusz Z.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (05): : 413 - 420
  • [35] A Novel Aurora-a Kinase Inhibitor MLN8237 Induces Cytotoxicity and Cell Cycle Arrest in Experimental Multiple Myeloma Models
    Gorgun, Gullu
    Calabrese, Elisabetta
    Mani, Mala
    Hideshima, Teru
    Ikeda, Hiroshi
    Perrone, Giulia
    Santo, Loredana
    Cirstea, Diana
    Blotta, Simona
    Richardson, Paul G.
    Ecsedy, Jefrrey
    Anderson, Kenneth C.
    BLOOD, 2008, 112 (11) : 605 - 606
  • [36] The effect of esomeprazole, a proton pump inhibitor, on the pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors or lymphomas
    Zhou, X.
    Nemunaitis, J.
    Pant, S.
    Bauer, T.
    Lockhart, A.
    Patel, M.
    Zhang, B.
    Kelly, V.
    Ullmann, C. D.
    Bargfrede, M.
    Venkatakrishnan, K.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 21 - 22
  • [37] Synergistic Cytotoxic Effect of the Microtubule Inhibitor Marchantin A from Marchantia polymorpha and the Aurora Kinase Inhibitor MLN8237 on Breast Cancer Cells In Vitro
    Jensen, J. Sophie R. E.
    Omarsdottir, Sesselja
    Thorsteinsdottir, Jenny B.
    Ogmundsdottir, Helga M.
    Olafsdottir, Elin S.
    PLANTA MEDICA, 2012, 78 (05) : 448 - 454
  • [38] Antitumor activity of the Aurora A inhibitor MLN8237 in combination with Docetaxel in xenograft models of breast and prostate cancer
    Huck, Jessica
    Zhang, Mengkun
    Hyer, Marc
    Yu, Li
    Stringer, Bradley
    Yang, Yu
    Ecsedy, Jeffrey
    Manfredi, Mark
    CANCER RESEARCH, 2009, 69
  • [39] Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237)
    Goos, Jeroen A. C. M.
    Verbeek, Joost
    Geldof, Albert A.
    Hiernstra, Annemieke C.
    van de Wiel, Mark A.
    Adamzek, Kevin A.
    Delis-Van Diemen, Pien M.
    Stroud, Stephen G.
    Bradley, Daniel P.
    Meijer, Gerrit A.
    Hoekstra, Otto S.
    Fijneman, Remond J. A.
    Windhorst, Albert D.
    NUCLEAR MEDICINE AND BIOLOGY, 2016, 43 (01) : 63 - 72
  • [40] A Novel Aurora-A Inhibitor (MLN8237) Synergistically Enhances the Antitumor Activity of Sorafenib in Hepatocellular Carcinoma
    Zhang, Kai
    Wang, Ting
    Zhou, Hao
    Feng, Bing
    Chen, Ying
    Zhi, Yingru
    Wang, Rui
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2018, 13 : 176 - 188
12345